Vernakalant - A promising therapy for conversion of recent-onset atrial fibrillation

Expert Opinion on Investigational Drugs

Volumn 17, Issue 5, 2008, Pages 805-810

  Naccarelli, Gerald V ^a   Wolbrette, Deborah L ^a   Samii, Soraya ^a   Banchs, Javier E ^a   Penny Peterson, Erica ^a   Stevenson, Robert ^a   Gonzalez, Mario D ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Antiarrhythmic agents; Atrial fibrillation; Vernakalant

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P450; DIGOXIN; DOFETILIDE; IBUTILIDE; INWARDLY RECTIFYING POTASSIUM CHANNEL; KYNAPID; PLACEBO; POTASSIUM CHANNEL KV1.5; QUINIDINE; SHAL POTASSIUM CHANNEL; SOTALOL; VERNAKALANT; VOLTAGE DEPENDENT ANION CHANNEL; ANISOLE DERIVATIVE; ION CHANNEL; PYRROLIDINE DERIVATIVE;

ACUTE CORONARY SYNDROME; AORTA STENOSIS; ASPIRATION; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; BURN; CARDIOVERSION; CATHETER ABLATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; COUGHING; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG WITHDRAWAL; DYSGEUSIA; ELECTROPHYSIOLOGY; FLUID INTAKE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART REPOLARIZATION; HEART VALVE REPLACEMENT; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; INDUCED HYPOTENSION; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; PACEMAKER FAILURE; PARESTHESIA; PRURITUS; PULMONARY VEIN OBSTRUCTION; QT INTERVAL; QT PROLONGATION; RECURRENT DISEASE; REVIEW; SIDE EFFECT; SINUS ARREST; SNEEZING; SUSTAINED DRUG RELEASE; TORSADE DES POINTES; DRUG ANTAGONISM; DRUG SCREENING; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANISOLES; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION; ELECTRIC COUNTERSHOCK; ELECTROPHYSIOLOGY; HUMANS; INJECTIONS, INTRAVENOUS; ION CHANNELS; PYRROLIDINES; RECURRENCE;

EID: 44449088060     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.5.805     Document Type: Review

References (18)

1. Naccarelli GV, Wolbrette DL, Khan M, et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Am J Cardiol 2003;91:15D-26D
2. Daoud EG. Percutaneous catheter ablation of atrial fibrillation. Expert Rev Cardiovasc Ther 2007;59:693-705
3. Choudhury A. Lip GY. Antiarrhythmic drugs in atrial fibrillation: an overview of new agents, their mechanisms of action and potential clinical utility. Expert Opin Investig Drug 2004;13:841-55
4. Naccarelli GV, Wolbrette, Samii S, et al. New antiarrhythmic treatment of atrial fibrillation. Expert Rev Cardiovasc Ther 2007;5:707-14
5. Fedida D, Orth P Chen J, et al. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol 2006;16:1227-38
6. Roy D, Rowe BH, Stiell IG, et al. for the CRAFT Investigators. A randomized, controlled trial of RSD 1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol 2004;44:2355-61
7. Fedida D. Vernakalant (RSD1235): a novel, atrial selective antifibrillatory agent. Expert Opin Investig Drugs 2007;16:519-32
8. Dia EQ, Rathbun RA, Song JC. Vernakalant: a novel antiarrhythmic agent for the treatment of atrial fibrillation. Formulary 2007;42:475-83
9. Nattel S, Carlsson L. Innovative approaches to anti-arrhythmic therapy. Nat Rev Drug Discov 2006;5:1034-49
10. Na and suppresses early afterdepolarizations and torsades de pointes induced by class III agents. Cardiovasc Res 2006;70:486-96
11. Na and antiarrhythmic drugs in EAD formation and termination in Purkinje fibers. J Cardiovasc Electrophysiol 2006;17:S71-8
12. Dorian P, Pinter A, Mangat I, et al. The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent on atrial electrophysiology in humans. J Cardiovasc Pharmacol 2007;50:35-40
13. Roy D, Pratt C, Wyse DG, et al. RSD1235 for conversion of atrial fibrillation. The phase III Atrial Arrhythmia Conversion Trial. Presented at the Heart Rhythm Society 2005 26th Annual Scientific Sessions; New Orleans, LA, USA; 2005
14. Pratt C, Roy D, Juul-Moller S, et al. Efficacy and tolerance of RSD1235 in the treatment of atrial fibrillation or atrial flutter: results of a phase III, randomized, placebo-controlled, multicenter trial [abstract 47]. J Am Coll Cardiol 2006;10A
15. Pratt CM, Navratil J, Nagy A, et al. Oral vernakalant (RSD1235-SR) prevents recurrence of atrial fibrillation following cardioversion [abstract 4]. Heart Rhythm 2007;S176
16. Roy D, Pratt C, Camm, AJ, et al. RSD1235 effectively converts atrial fibrillation to sinus rhythm independent of background use of oral rate- or rhythm-control medications [abstract 114]. Circulation 2006;II-790
17. Kowey PR, Roy D, Pratt CM, et al. Efficacy and safety of vernakalant hydrochloride injection for the treatment of atrial fibrillation after valvular or coronary artery bypass surgery [abstract 16]. Circulation 2007;II-636
18. Astellas Pharma US, Inc. Briefing materials for the cardiovascular and renal drugs advisory committee: December 11, 2007 - Kynapid™ (vernakalant hydrochloride injection). NDA 22-034